IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN-Reference-Cited by-同舟云学术

IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN

Published:2017-06 Issue: Volume:35 Page:117-119
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Hiddemann W.¹,Barbui A.M.²,Canales Albendea M.A.³,Cannell P.K.⁴,Collins G.P.⁵,Dürig J.⁶,Forstpointner R.¹,Herold M.⁷,Hertzberg M.⁸,Klanova M.⁹,Radford J.A.¹⁰,Tobinai K.¹¹,Burciu A.¹²,Fingerle-Rowson G.R.¹³,Nielsen T.¹³,Wolbers M.¹⁴,Marcus R.¹⁵

Affiliation:

1. Department of Medicine III; Ludwig-Maximilians-University Hospital Munich; Munich Germany

2. Department of Hematology; Azienda Ospedaliera Papa Giovanni XXIII; Bergamo Italy

3. Department of Medicine; Hospital Universitario la Paz; Madrid Spain

4. Haematology Department; Fiona Stanley Hospital; Murdoch Australia

5. Department of Clinical Haematology; Oxford Cancer and Haematology Centre, Churchill Hospital; Oxford UK

6. Medical Faculty (Haematology), Universitaetsklinikum Essen; Essen Germany

7. Oncology Center; HELIOS-Klinikum Erfurt; Erfurt Germany

8. Department of Haematology; Prince of Wales Hospital; Sydney Australia

9. 1st Department of Medicine; Charles University General Hospital, Prague, Czech Republic and Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd; Basel Switzerland

10. Manchester Academic Health Science Centre; The University of Manchester and The Christie NHS Foundation Trust; Manchester UK

11. Department of Hematology; National Cancer Center Hospital; Tokyo Japan

12. Pharma Development Safety and Risk Management; F. Hoffmann-La Roche Ltd; Basel Switzerland

13. Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland

14. Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd; Basel Switzerland

15. Department of Haematology; Kings College Hospital; London UK

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Management and Novel Approaches to the Management of Follicular Lymphoma;Follicular Lymphoma;2019-12-03

2. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy;British Journal of Clinical Pharmacology;2019-05-17

3. Front‐line management of non‐Hodgkin lymphoma in Australia. Part 1: follicular lymphoma;Internal Medicine Journal;2019-04

4. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States;Leukemia & Lymphoma;2019-01-11

5. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study;Journal of Clinical Oncology;2018-08-01